Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous paricalcitol in hemodialysis patients with secondary hyperparathyroidism
ChiCTR2000032353Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Hemoglobin, Intact parathyroid hormone and 10 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on ChiCTR2000032353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032353.